Brian Strem EyeGate Pharmaceuticals (NASDAQ:EYEG) appointed Brian Strem, Ph.D., as president, CEO and a director, effective immediately. He replaces acting CEO, Franz Obermayr, Ph.D., who reassumes his position as...
Alliance Global Partners reduced its price target for EyeGate Pharmaceuticals (NASDAQ:EYEG) to $10.25 from $16.75, citing a possible plan to sell additional common shares in the first half of this year in order to...
Alliance Global Partners launched coverage of EyeGate Pharmaceuticals (NASDAQ:EYEG) with a “buy” rating and price target of $9.50, representing a price-to-sales multiple of eight times based on 2022 revenue estimates...
By Len Zehr EyeGate Pharmaceuticals (NASDAQ:EYEG) is developing a non-invasive drug delivery platform that uses an electrical process, known as iontophoresis, to deliver a corticosteroid to the front-and back-of-the-eye...